-
www.uspreventiveservicestaskforce.org/uspstf/document/draft-research-plan/breast-cancer-medication-use-reduce-risk
December 28, 2023 - What is the effectiveness of risk-reducing medications on primary invasive breast cancer, breast cancer … What are the harms of medications used to reduce primary breast cancer risk? … What are the current practices of primary care clinicians on breast cancer risk-reducing medications … Use of medications for treatment or prevention of other outcomes (e.g., breast cancer reoccurrence, … to prevent primary breast cancer (tamoxifen, raloxifene, or aromatase inhibitors)
Medications not
-
www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/breast-cancer-medication-use-reduce-risk
March 21, 2024 - What is the effectiveness of risk-reducing medications on primary breast cancer, breast cancer mortality … What are the harms of medications used to reduce primary breast cancer risk? … Category
Include
Exclude
Aim
The use of medications to prevent primary breast cancer … Use of medications for treatment or prevention of other outcomes (e.g., breast cancer reoccurrence, … to prevent primary breast cancer (tamoxifen, raloxifene, or aromatase inhibitors)
Medications not
-
www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/breast-cancer-medications-for-risk-reduction
July 20, 2017 - Women may experience adverse effects due to these medications. … Does the effectiveness of risk-reducing medications persist beyond discontinuation of use? … What are the harms of using medications to reduce risk for primary breast cancer? … Do the harms of risk-reducing medications vary by timing of initiation or duration of use? … Do the harms of risk-reducing medications persist beyond discontinuation of use?
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/eUBUXRUJHua5Q44j_THFn2
Medications for Risk Reduction of Primary Breast Cancer in Women: Clinical Summary of USPSTF Recommendation … MEDICATIONS FOR RISK REDUCTION OF PRIMARY BREAST CANCER IN WOMEN
CLINICAL SUMMARY OF U.S. … Recommendation
Engage in shared, informed decision making and offer to
prescribe risk-reducing medications … Grade: B
Do not prescribe risk-reducing medications. … Preventive Medications
The selective estrogen receptor modulators tamoxifen and raloxifene have been
-
www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction
September 03, 2019 - Vasomotor symptoms (hot flashes) are a common adverse effect of both medications. … 6 and should be offered these medications if their risk of harms is low. … See below for more information on potential harms from risk-reducing medications. … Effectiveness of medications (within trials) did not vary by age or menopausal status. … Medications to decrease the risk for breast cancer in women: U.S.
-
www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/breast-cancer-medications-for-risk-reduction
September 03, 2019 - Vasomotor symptoms (hot flashes) are a common adverse effect of both medications. … 6 and should be offered these medications if their risk of harms is low. … See below for more information on potential harms from risk-reducing medications. … Effectiveness of medications (within trials) did not vary by age or menopausal status. … Medications to decrease the risk for breast cancer in women: U.S.
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/-TsBkyewVoFpC7htRmzWJa
September 03, 2019 - Do the harms of risk-reducing medications persist beyond discontinuation of use? … Benefits of Risk-Reducing Medications
Key Question 2. … Harms of Risk-Reducing Medications
Key Question 3. … What are the harms of using medications to re-
duce risk for primary breast cancer? … Do the harms of risk-reducing medications per-
sist beyond discontinuation of use?
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/3Kwu7j_WfCFQSnSzqrDWwt
June 20, 2019 - OBJECTIVE To update the 2013 US Preventive Services Task Force (USPSTF) recommendation
on medications … Vasomotor symptoms (hot
flashes) are a common adverse effect of both medications. … See below for more information on potential harms from risk-
reducing medications. … Medications to decrease the risk for breast cancer
in women: recommendations from the U.S. … Clinical preventive service
recommendation: medications to reduce breast
cancer risk.
-
www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction-2013
September 15, 2013 - Print
archived
Final Recommendation Statement
Breast Cancer: Medications … Grade: B
Do not prescribe risk-reducing medications. … Effectiveness of Risk-Reducing Medications
To understand the effectiveness of risk-reducing medications … Both medications reduced breast cancer risk in postmenopausal women. … Comparative Effectiveness of Medications to Reduce Risk of Primary Breast Cancer in Women.
-
www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-cancer-medications-for-risk-reduction
September 03, 2019 - groups or direct comparisons between the medications were included. … Harms of Risk-Reducing Medications
Key Question 3. … What are the harms of using medications to reduce risk for primary breast cancer? … Do the harms of risk-reducing medications persist beyond discontinuation of use? … prescribe medications; lack of comfort or certainty with identifying women eligible for medications;
-
www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/cognitive-impairment-older-adults
June 12, 2025 - galantamine, rivastigmine)
NMDA (N-methyl-D-aspartate) receptor antagonists (memantine)
Cessation of medications … )
Cognitive impairment pharmacotherapies discontinued by the manufacturer (tacrine, aducanumab)
Medications … used to treat cerebrovascular disease (e.g., antiplatelet medications, antihypertension medications, … Serious adverse events (e.g., death, serious adverse drug reactions), total adverse reactions from medications … However, these medications (statins, antihypertensives, and hyperglycemic agents) are not FDA-approved
-
www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction-2002
July 08, 2002 - Print
archived
Final Recommendation Statement
Breast Cancer: Medications
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/zVVRY6wa4Sgj-EJb3BRcVy
November 01, 2013 - Medications for Risk Reduction of Primary Breast Cancer in Women:
U.S. … Preventive Services Task
Force (USPSTF) recommendation on the use of medications for
breast cancer risk … Medications for risk reduction of primary breast cancer in women: clinical summary of U.S. … MEDICATIONS FOR RISK REDUCTION OF PRIMARY BREAST CANCER IN WOMEN
CLINICAL SUMMARY OF U.S. … Both medications reduced breast cancer risk in post-
menopausal women.
-
www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary27/breast-cancer-medications-for-risk-reduction-2013
April 15, 2013 - of medications to reduce risk for breast cancer is low in the United States 12 . … Interventions include FDA-approved medications to reduce risk for primary breast cancer. … We requested scientific information packets from manufacturers of medications. … Both medications reduced fractures. … medications, with tamoxifen causing 4 more events per 1000 women than raloxifene in STAR.
-
www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/cognitive-impairment-in-older-adults-screening
October 19, 2017 - or dietary supplements:
Medications aimed at cardiovascular risk reduction for treatment of vascular … dementia (antiplatelet medications, antihypertension medications, HMG-CoA reductase inhibitors)
Nonsteroidal … B vitamins and folate, vitamins C and E, beta-carotene, omega-3 fatty acids)
Cessation of medications … that may be contributing to cognitive impairment (e.g., anticholinergic medications, benzodiazepines … (i.e., antipsychotics, antiepileptics, antidepressants, selective serotonin reuptake inhibitors)
Medications
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/7ZSKduUYHWKe7q_tTY9xbF
April 01, 2013 - Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review of the USPSTF
Use … of Medications to Reduce Risk for Primary Breast Cancer:
A Systematic Review for the U.S. … Griffin, MS; and Rongwei Fu, PhD
Background: Medications to reduce risk for primary breast cancer
are … We requested scientific information
packets from manufacturers of medications. … Both medications reduced fractures.
-
www.uspreventiveservicestaskforce.org/home/getfilebytoken/Z3BVaJRtyu8drWSHWYT_Yf
35 y not at increased risk for breast cancer
Recommendation
Offer to prescribe risk-reducing medications … as tamoxifen,
raloxifene, or aromatase inhibitors
Grade: B
Do not routinely use risk-reducing medications … When considering prescribing breast cancer risk-reducing medications, the potential benefit of risk reduction … Risk-Reducing
Medications
Tamoxifen, raloxifene, and aromatase inhibitors all reduce primary breast
-
www.uspreventiveservicestaskforce.org/uspstf/document/draft-research-plan/cognitive-impairment-older-adults
March 06, 2025 - galantamine, rivastigmine)
NMDA (N-methyl-D-aspartate) receptor antagonists (memantine)
Cessation of medications … )
Cognitive impairment pharmacotherapies discontinued by the manufacturer (tacrine, aducanumab)
Medications … used to treat cerebrovascular disease (e.g., antiplatelet medications, antihypertension medications, … Serious adverse events (e.g., death, serious adverse drug reactions), total adverse reactions from medications
-
www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan151/lipid-disorders-in-children-screening-july-2016
January 15, 2015 - A subsequent branch leads to treatment (medications, lifestyle modifications), and an arrow from treatment … Does treatment of familial hypercholesterolemia with lifestyle modifications and/or lipid-lowering medications … What are the harms of treatment of familial hypercholesterolemia with medications in children and adolescents … Does treatment of multifactorial dyslipidemia with lifestyle modifications and/or lipid-lowering medications … Does treatment of multifactorial dyslipidemia with lifestyle modifications and/or lipid-lowering medications
-
www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/genital-herpes-screening-november-2016
August 06, 2015 - How effective are oral antiviral medications in reducing genital HSV-2 viral shedding in asymptomatic … How effective are preventive medications and behavioral counseling interventions in reducing neonatal … What are the harms of preventive medications and behavioral counseling interventions for reducing future … What are the harms of preventive medications and behavioral counseling interventions for reducing neonatal … vs. placebo
KQ 6b: Oral antiviral medications vs. placebo or no intervention
KQs 5, 6: Behavioral